JPRN-jRCT2080220803未知2 期
Phase 2 Dose-Finding Study of JTT-305 in Patients with Primary Osteoporosis.
JAPAN TABACCO INC.0 个研究点目标入组 320 人开始时间: 2009年8月14日最近更新:
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 45age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •More than 5 years since menopause
- •- < 70% of YAM at lumbar spine
- •- < 80% of YAM at lumbar spine with one mild vertebral fracture
排除标准
- •- Vertebral fractures on the 1st to 4th lumbar spine
- •- History of drug use;
- •1) Strontium ranelate, anti-RANKL antibody preparations, or parathyroid hormone preparations
- •2) Bisphosphonates within 1 year of the screening visit
研究者
相似试验
招募中
2 期
Dose finding study of JTE-051Interstitial Cystitis/Bladder Pain SyndromeJPRN-jRCT2031210042Koretomo Ryosuke150
招募中
不适用
Randomized phase II study of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabinepatients with unresectable advanced or recurrent pancreatic cancerJPRN-UMIN000027631agoya University56
招募中
2 期
RCT of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus GemcitabinePancreatic cancerPncreatic cancerJPRN-jRCTs041190040Kodera Yasuhiro56
招募中
1 期
Dermal Safety Study of JTE-052atopic dermatitisJPRN-jRCT2031230570Koretomo Ryosuke22
撤回
2 期
Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionNCT03789643Akros Pharma Inc.